FDA reviews Boehringer's Spiriva HandiHaler for stroke risk

The FDA announced Tuesday that it is conducting a safety review of Boehringer Ingelheim's Spiriva HandiHaler, a treatment for chronic obstructive pulmonary disease, after the company reported that it may increase the risk of stroke. The agency has asked the company to submit more data on the inhaler but warned patients against discontinuing treatment without proper medical advice.

View Full Article in:

Washington Post (tiered subscription model), The · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC